What are your top takeaways from ASCO GU 2022?  

My top abstracts and questions that arise from them:   1) ARASENS with darolutamide in high volume de novo mHSPC showing an OS benefit with darolutamide over ADT/docetaxel. Will this pertain only to high volume/risk patients who are chemo-fit and de novo which seemed to comprise the vast ...

My top 3 studies are: ARASENS MAGNITUDE PROpel The main question after ARASENS trial: Do we give triplet treatment for all newly diagnosed metastatic hormone-sensitive prostate cancer? If not, who will be the ideal patient for triplet treatment vs doublet?  MAGNITUDE and PROpel: Are we...

Given positive and new data: 1. QUILT 3.032: Intravesical N803 (IL-15 superagonist) + BCG for BCG-unresponsive NMIBC: CIS group (n=83)-CR=71%, median duration of response (DOR)=24.1 months (mo); Papillary group (n=77)- median DFS 23.6 mo; no therapy related severe adverse events. Results show prom...

For Rad Onc: NRG digital path study as biomarker is important for intermediate risk prostate cancer. Future will be biomarker. This raises the question: Will this be commercially available in the future? MRI vs CT for SBRT from UCLA. Here it's more a question of margins and tracking. Will be int...

ARASENS:  Data from ARASENS provides additional supportive data for selected patients presenting with high risk de novo metastatic prostate cancer to receive ADT/docetaxel and an ARI currently abi, but this study will result in broadening of the FDA label of darlutamide.  PROpel, MAGNIT...

ARASENS Adjuvant Pembro in RCC HCRN renal study (Atkins)